Acute and long-term antiplatelet therapy
Loading...
Date
Authors
Papathanasiou, A. I.
Goudevenos, J. A.
Mikhailidis, D. P.
Tselepis, A. D.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer reviewed
Educational material type
Conference Name
Journal name
Drugs of Today
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Clinical presentations of atherothrombotic vascular disease, i.e., acute coronary syndromes, cerebrovascular events and events associated with peripheral arterial disease, are the major causes of mortality and morbidity worldwide. Platelet activation and aggregation play an important role in the progression and clinical presentation of atherothrombotic disease, and antiplatelet therapy improves outcome in patients with atherothrombotic vascular disease. Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha(IIb)beta(3)) inhibitors have also shown similar effectiveness. This review briefly summarizes the major clinical trials and recommendations for the efficacy and safety of antiplatelet therapy in patients with established atherothrombotic disease. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Description
Keywords
platelet glycoprotein iib/iiia, acute coronary syndromes, acute myocardial-infarction, st-segment elevation, peripheral arterial-disease, placebo-controlled trial, low-dose aspirin, american-heart-association, transient ischemic attack, high-risk patients
Subject classification
Citation
Link
<Go to ISI>://000256918300003
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας